PreClinical Pathfinder leadership has extensive scientific and industry expertise to ensure success in the development and execution of your preclinical project.


Rabi Hanna | President & Chief Medical Director

Dr. Hanna, Chairman of Cleveland Clinic Department of Pediatric Hematology Oncology and Blood and Marrow Transplantation, is board certified in pediatrics and pediatric hematology-Oncology. He earned his medical degree from Aleppo University Faculty of Medicine in Aleppo, Syria.

Dr. Hanna is a member of several professional organizations, including the American Society of Pediatric Hematology Oncology, American Society of Hematology, and the American Society of Bone Marrow Transplant.

Connect with Rabi on LinkedIn


Gabi Hanna, M.D. | CEO

Dr. Hanna is co-founder and partner of Preclinical Pathfinder Systems. He is a physician and has expertise in surgery and preclinical models. He is also Chairman of the North Carolina chapter of the Society for Physician Entrepreneurs.

 Connect with Gabi on LinkedIn


Greg Palmer, PhD | Chief Scientific Officer

He has over 50 peer reviewed publications, with an emphasis on development and translation of optical sensing techniques for quantification of tissue physiology and treatment response. He also has 3 commercially licensed patents. Dr. Palmer\’s role as Chief Scientific Officer is to provide scientific oversight and guidance on all projects, and foster a collaborative scientific relationship.

Connect with Greg on LinkedIn


Francis Chester | VP of Government Contracts

He has an extensive background in federal contracting and is the Chairman of the North Carolina Defense Business Association (2016-2017), a group of over 250 companies focused on increasing government contracting in North Carolina. Francis also serves on the board of directors of the Sandhills Military Council.

Connect with Francis on LinkedIn

Preclinical Services

We offer a comprehensive suite of early stage preclinical drug development services. Visit our Services page to learn more.


Having access to scientific and industry expertise is crucial to the success to any preclinical drug development process. This collaborative approach is a fundamental part of our value added process.